Almirall and SPS announce 2006 pharmacology award
Spanish pharmaceutical company Almirall says that Concepcion Peiro from the Autonomous University of Madrid, has been awarded the 2006 pharmacology award as funding for the project "Insulin resistance, endothelial dysfunction and vascular inflammation: role of adipokines."
The award, which is jointly promoted by the firm and the Spanish Pharmacological Society (SPS), is worth 9,000 euros ($11,342) and was announced at the society's 28th congress in Santiago de Compostela. Dr Peiro will carry out the work this year, with the aim of presenting her findings at the next conference.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze